46 results about "Aminoquinolines" patented technology

The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

The invention relates to a method for inhibiting FLT3 tyrosine kinase activity or expression, or reducing FLT3 kinase activity or expression in cells or patients, the method comprising administering a farnesyltransferase inhibitor and a FLT3 kinase inhibitor, wherein the FLT3 kinase inhibitor is selected from Aminoquinoline and aminoquinazoline compounds of formula (I'): wherein R1, R2, R3, B, Z, Q, p, q and X are as defined herein. The present invention includes prophylactic and therapeutic methods of treating patients at risk of (or susceptible to) developing a cell proliferative disorder or a disorder associated with FLT3.

Various 2-aminoquinoline compounds as can be used, in vivo or in vitro, for selective inhibition of neuronal nitric oxide synthase.

The present invention relates to 2-aminoquinolines of formula Iwherein R1, R2 and R3 are as defined in the specification, as 5-HT5A receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use for the treatment of CNS disorders.

The present invention provides a method for mass spectrometry of phosphorylated peptides or sugar chains, which suppresses the desorption of an unstable site during ionization and achieves high sensitivity (i.e., detects molecular-related ions at a high ionic strength and at a relatively higher ionic strength than other ion species derived from the desorption of an unstable site). A method for mass spectrometry of phosphorylated peptides or sugar chains, the method comprising using, as a liquid matrix, an ionic liquid comprising a 3-aminoquinoline ion and a p-coumaric acid ion. The liquid matrix comprises 3-aminoquinoline and p-coumaric acid, for example, in a molar ratio of 5:1 to 20:1. Ammonium phosphate may be used as an additive.

The invention discloses a synthesis method of a dihydropyrrolo2-aminoquinoline compound. The synthesis method comprises the following steps: in a reactor, dissolving high-alkyne propylamine, a catalyst, an oxidant and a ligand into an organic solvent, and then adding isocyanide; stirring and reacting at 80 to 100 DEG C; after reaction is finished, cooling a reaction solution to room temperature; separating and purifying the reaction solution to obtain the dihydropyrrolo2-aminoquinoline compound. The synthesis method disclosed by the invention takes the simple and easy-to-obtain high-alkyne propylamine as a raw material, and isocyanide migration and inserting serial cyclization reaction is carried out; common palladium salt is used as the catalyst, and cheap copper salt is used as an oxidant to construct the dihydropyrrolo2-aminoquinoline compound with extremely good medicinal value; the synthesis method has the advantages of simple and easy-to-obtain raw materials, simplicity and safety in operation, moderate conditions and high atom economy; the synthesis method has the characteristics of high efficiency, convenience, wide applicable range and the like in the synthesis of a targetproduct and has potential value in actual production and application.

The invention relates to the technical field of medicine, in particular to a class of aminoquinoline compounds, a preparation method thereof and an antifungal application thereof. The aminoquinoline compounds provided by the invention generally have good antifungal activity and have the potential to be developed into non-azole antifungal drugs.

The invention provides methods of preparing macrocycles including macrocycle stabilized peptides (MSPs). Macrocycles and MSPs are prepared according to nucleophilic capture of an iminoquinomethide type intermediate generated from a suitably substituted 2-amino-thiazol-5-yl carbinol. The preferred nucleophile may be selected from an electron rich aromatic moiety in the case of macrocycles and, in the case of MSPs, at least one amino acid comprises an electron rich aromatic moiety. In addition, the concept can be extended to other related 5-membered heterocyclic systems in place of the thiazole, such as imidazole or oxazole. The conditions for the generation of the corresponding iminoquinomethide type intermediates may be similar or different than the conditions used for the 2-amino-thiazol-5-yl carbinol.